placeholder image
member of the LEAD-6 Study Group All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 
    Lancet (London, England). 2009
    • Contact
    full name
  • member of the LEAD-6 Study Group
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration